Chemed’s (CHE) Sector Perform Rating Reiterated at Royal Bank Of Canada

Royal Bank Of Canada reaffirmed their sector perform rating on shares of Chemed (NYSE:CHE) in a research note released on Friday, Marketbeat.com reports. The brokerage currently has a $422.00 price objective on the stock, down from their prior price objective of $572.00.

Several other equities analysts have also weighed in on CHE. Jefferies Financial Group lowered shares of Chemed from a “buy” rating to a “hold” rating in a research report on Thursday, January 22nd. Zacks Research upgraded shares of Chemed from a “strong sell” rating to a “hold” rating in a research note on Thursday, October 30th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Chemed in a report on Wednesday, January 21st. Two analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, Chemed has an average rating of “Hold” and an average target price of $498.00.

Chemed Trading Up 3.4%

CHE opened at $410.14 on Friday. The stock has a fifty day moving average price of $446.06 and a 200 day moving average price of $443.85. Chemed has a 1 year low of $385.00 and a 1 year high of $623.60. The stock has a market cap of $5.81 billion, a price-to-earnings ratio of 22.33, a PEG ratio of 1.52 and a beta of 0.47.

Chemed (NYSE:CHE) last issued its earnings results on Wednesday, February 25th. The company reported $6.42 earnings per share for the quarter, missing the consensus estimate of $7.02 by ($0.60). The firm had revenue of $639.34 million during the quarter, compared to analyst estimates of $659.09 million. Chemed had a return on equity of 25.66% and a net margin of 10.48%.The business’s revenue for the quarter was down .1% on a year-over-year basis. During the same period in the previous year, the company earned $6.83 earnings per share. Chemed has set its FY 2026 guidance at 23.250-24.250 EPS. As a group, sell-side analysts forecast that Chemed will post 21.43 earnings per share for the current fiscal year.

Chemed Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 13th. Investors of record on Monday, February 23rd will be issued a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Monday, February 23rd. Chemed’s dividend payout ratio is currently 13.06%.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of CHE. Alps Advisors Inc. grew its holdings in Chemed by 32.4% in the 3rd quarter. Alps Advisors Inc. now owns 44,295 shares of the company’s stock valued at $19,833,000 after buying an additional 10,845 shares during the last quarter. Vest Financial LLC lifted its holdings in shares of Chemed by 32.6% during the third quarter. Vest Financial LLC now owns 9,702 shares of the company’s stock worth $4,344,000 after buying an additional 2,383 shares during the last quarter. Envestnet Asset Management Inc. boosted its position in shares of Chemed by 6.5% in the third quarter. Envestnet Asset Management Inc. now owns 80,080 shares of the company’s stock valued at $35,855,000 after acquiring an additional 4,865 shares during the period. Van Berkom & Associates Inc. grew its stake in shares of Chemed by 33.0% in the third quarter. Van Berkom & Associates Inc. now owns 170,813 shares of the company’s stock worth $76,480,000 after acquiring an additional 42,390 shares during the last quarter. Finally, Jupiter Asset Management Ltd. grew its stake in shares of Chemed by 35.0% in the second quarter. Jupiter Asset Management Ltd. now owns 69,563 shares of the company’s stock worth $33,872,000 after acquiring an additional 18,047 shares during the last quarter. Institutional investors own 95.85% of the company’s stock.

Chemed News Roundup

Here are the key news stories impacting Chemed this week:

• Positive Sentiment: Oppenheimer lowered its price target but kept an “outperform” rating (PT cut to $500), signaling some analysts still see multi‑quarter upside despite the recent miss. Oppenheimer PT/Rating
• Neutral Sentiment: RBC reaffirmed a “sector perform” rating and set a $422 target (down from $572), reflecting a more cautious stance but not a full downgrade; this indicates mixed analyst conviction. RBC note
• Neutral Sentiment: Chemed issued FY‑2026 EPS guidance of $23.25–$24.25 (roughly in line but slightly below consensus), and said ~55% of 2026 earnings are likely back‑half weighted as it executes transition initiatives — guidance tempers but does not eliminate investor concern. Earnings release / guidance
• Neutral Sentiment: Full Q4 earnings and conference-call transcripts were posted (Seeking Alpha, Yahoo, others); these provide management commentary on margin compression, VITAS trends and cash‑flow dynamics for investors doing deeper diligence. Earnings call transcript
• Negative Sentiment: Zacks highlights the headline: Q4 EPS and revenue missed consensus, margins contracted and the FY‑2026 EPS outlook came in below street expectations — the earnings shock was the primary catalyst for the sharp share drop. Zacks: Earnings & margins miss
• Negative Sentiment: Detailed quarter metrics (QuiverQuant) show revenue and EPS declines, steeper drops in operating cash flow and lower cash balances — these raise near‑term liquidity and execution risk concerns for investors. QuiverQuant: Financial details
• Negative Sentiment: Johnson Fistel announced an investigation into possible claims tied to Chemed executives — potential litigation risk can amplify selling pressure and valuation uncertainty. GlobeNewswire: Investigation notice
• Negative Sentiment: BofA cut Chemed to neutral after the Q4 miss — another sign of weakening analyst conviction that can pressure sentiment until evidence of margin/cash‑flow stabilization appears. MSN / BofA note

About Chemed

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.